Last update Feb. 12, 2019

Ornidazole

Low Risk

Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

A bactericidal antibiotic from the family of 5-nitro-imidazoles. Similar in properties and action to metronidazole.
Indicated in infections from anaerobic and parasitic bacteria (Trichomonas vaginalis, Giardia intestinalis, Entamoeba histolytica).
Oral or intravenous administration in two daily doses.

Since the last update we have not found published data on its excretion in breastmilk.

Its pharmacokinetic data (low molecular weight, poor plasma protein binding) make it likely it will transfer to milk in potentially significant amounts.
Its use in newborns and infants has been proposed (Trucan 1987).

Because there are fewer published studies than for other drugs from the same group, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity.

Alternatives

  • Metronidazole ( Safe. Compatible. Minimal risk for breastfeeding and infant.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Ornidazole in other languages or writings:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 90 %
Molecular weight 220 daltons
Protein Binding 11 - 13 %
VD 0.7 - 0.9 l/Kg
Tmax 1.2 - 4 hours
12 - 17 hours

References

  1. Teva-Pharm. Ornidazole. Drug Summary. 2017 Full text (in our servers)
  2. Roche. Ornidazol. Ficha técnica. 2001 Full text (in our servers)
  3. Lamp KC, Freeman CD, Klutman NE, Lacy MK. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin Pharmacokinet. 1999 Abstract
  4. Turcant A, Granry JC, Allain P, Cavellat M. Pharmacokinetics of ornidazole in neonates and infants after a single intravenous infusion. Eur J Clin Pharmacol. 1987 Abstract
  5. Andersson KE. Pharmacokinetics of nitroimidazoles. Spectrum of adverse reactions. Scand J Infect Dis Suppl. 1981 Abstract

Total visits

8,423

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM